๊ฑฐ๋ž˜์†Œ
์ค‘์•™ํ™” ๊ฑฐ๋ž˜์†Œ
ํƒˆ์ค‘์•™ํ™” ๊ฑฐ๋ž˜์†Œ

Amgen ์ฃผ๊ฐ€
AMGN
#72

โ‚ฉ537,213.70
ย ย 

0.05%

Amgen Info

์‹œ๊ฐ€์ด์•ก
โ‚ฉ289.93T

0.05%

์ผ๊ฐ„ ๊ฑฐ๋ž˜๋Ÿ‰
โ‚ฉ444.96B
์›น์‚ฌ์ดํŠธ
์ž์‚ฐ ์œ ํ˜•
Stock
์ง์›
28000
์„ค๋ฆฝ
Apr 8, 1980
์ฃผ ๊ฑฐ๋ž˜์†Œ
Nasdaq
์‚ฐ์—…
Biological Products, (No Diagnostic Substances)
CIK ๋ฒˆํ˜ธ
0000318154

ํ† ํฐํ™”๋œ ์ฃผ์‹ ๋ฐ์ดํ„ฐ

ํ‰๊ท  ํ† ํฐํ™”๋œ ๊ฐ€๊ฒฉ
โ‚ฉ541.69K
๊ฐ€๊ฒฉ ์ฐจ์ด
+โ‚ฉ4.47K(+0.83%)
ํ† ํฐํ™”๋œ ์‹œ์ด
โ‚ฉ4.86M

0%

ํ† ํฐํ™”๋œ ๊ฑฐ๋ž˜๋Ÿ‰(24์‹œ๊ฐ„)
โ‚ฉ1.24B

3.66%

๋ฐœํ–‰์ธ
๊ณ„์•ฝ
์ต์Šคํ”Œ๋กœ๋Ÿฌ
AMGN USD ๋ณ€ํ™˜๊ธฐ
AMGN
KRW
๊ฐ€๊ฒฉ ํผํฌ๋จผ์Šค
๋‚ฎ์Œ
โ‚ฉ533.47K
๋†’์Œ
โ‚ฉ544.3K

๋ฐ์ดํ„ฐ ๋กœ๋”ฉ ์ค‘

์ž ์‹œ๋งŒ ๊ธฐ๋‹ค๋ ค ์ฃผ์„ธ์š”, ์ฐจํŠธ ๋ฐ์ดํ„ฐ๋ฅผ ๋กœ๋”ฉํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค

Amgen ์ปค๋ฎค๋‹ˆํ‹ฐ

skeleton-white
ย 
ย 
ย 
ย 
ย 
ย 

About Amgen

What is Amgen?

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen ๋ผ์ด๋ธŒ ๊ฐ€๊ฒฉ ๋ฐ์ดํ„ฐ

The current price of Amgen in the market is โ‚ฉ537,213.7, with a 24-hour trading volume of โ‚ฉ444.96B. The asset's market cap is โ‚ฉ289.93T, after moving -0.05% in the last day.

Tokenized Amgen is trading at โ‚ฉ541,692.15, with a tokenized market cap of โ‚ฉ4.86M and a 24-hour trading volume of โ‚ฉ1.24B. The tokenized asset has moved 0.00% in the past 24 hours.